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Macrolides, such as azithromycin (AZM) and clarithromycin, are the cornerstones of treatment forMycobacterium avium com-
plex lung disease (MAC-LD). Current guidelines recommend daily therapy with AZM for cavitary MAC-LD and intermittent
therapy for noncavitary MAC-LD, but the effectiveness of these regimens has not been thoroughly investigated. This study
evaluated associations betweenmicrobiological response and estimated peak plasma concentrations (Cmax) of AZM. The AZM
Cmax was measured in patients receiving daily therapy (250 mg of AZM daily, n 77) or intermittent therapy (500 mg of AZM
three times weekly, n 89) for MAC-LD and daily therapy forMycobacterium abscessus complex LD (MABC-LD) (250 mg of
AZM daily, n 55). The AZM Cmax was lower with the daily regimen for MAC-LD (median, 0.24g/ml) than with the intermit-
tent regimen for MAC-LD (median, 0.65g/ml; P< 0.001) or daily therapy for MABC-LD (median, 0.53g/ml; P< 0.001).
After adjusting for confounding factors, AZM Cmax was independently associated with favorable microbiological responses in
MAC-LD patients receiving a daily regimen (adjusted odds ratio [aOR], 1.58; 95% confidence interval [CI], 1.01 to 2.48; P
0.044) but not an intermittent regimen (aOR, 0.85; 95% CI, 0.58 to 1.23, P 0.379). With the daily AZM-based multidrug regi-
men for MAC-LD, a low AZM Cmax was common, whereas a higher AZM Cmax was associated with favorable microbiologic re-
sponses. The results also suggested that the addition of rifampinmay lower AZM Cmax. When a daily AZM-based multidrug regi-
men is used for treating severe MAC-LD, such as cavitary disease, the currently recommended AZM dose might be suboptimal.
(This study has been registered at ClinicalTrials.gov under identifier NCT00970801.)
Pulmonary disease caused by nontuberculous mycobacteria(NTM) is increasing worldwide (1, 2), and Mycobacterium
avium complex (MAC) is the most common etiology of lung dis-
ease (LD) due to NTM (1, 2). The introduction of newer macro-
lides, such as clarithromycin (CLR) and azithromycin (AZM), was
a major therapeutic advancement in the treatment of LD due to
MAC (MAC-LD) (3–8). However, conversion to negative sputum
culture is achieved in only 60% to 80% of patients receiving ma-
crolide-based regimens (9–12). The often unsuccessful results of
current treatment regimens are partly due to an incomplete un-
derstanding of the relationships between the dosages of the drugs
used and the level of exposure achieved in target organs, as deter-
mined by the pharmacokinetics and pharmacodynamics of the
drugs (13–15).
Therapeutic drug monitoring (TDM), that is, individualized
drug dosing guided by drug plasma concentrations, could be of
help in improving our understanding of drug interactions in the
current treatment regimens for MAC-LD (13–15). Rifampin
(RIF), one drug component of macrolide-based antibiotic regi-
mens for the treatment of MAC-LD, is well known to induce cy-
tochrome P450 isoenzymes and reduce peak plasma concentra-
tions (Cmax) of CLR and AZM (13–15). Although a lack of an
association between the Cmax of CLR and treatment outcomes was
reported (14), little is known regarding the relationship between
the Cmax of AZM and treatment outcomes of MAC-LD.
The current American Thoracic Society (ATS) and Infectious
Diseases Society of America (IDSA) guidelines recommend a daily
regimen of CLR or AZM, RIF, and ethambutol (EMB), with or
without the initial use of parenteral aminoglycoside, for patients
with fibrocavitary MAC-LD, cavitary nodular bronchiectatic
MAC-LD, or previously treated MAC-LD (3). For patients with
noncavitary nodular bronchiectatic MAC-LD, a three-times-
weekly intermittent regimen of CLR or AZM, RIF, and EMB is
recommended (3). Although the same CLR dose (1,000 mg) is
used in both the daily and intermittent regimens, different AZM
doses are recommended for the daily (250 to 300 mg) and inter-
mittent regimens (500 to 600 mg) for MAC-LD in the current
guidelines (3). This difference in dosing between CLR and AZM is
likely why the AZM Cmax differed significantly between patients
receiving 500-mg and 250-mg doses of AZM (13), whereas the
CLR Cmax values were similar in patients receiving daily and in-
termittent therapy for MAC-LD (14). The present study (Clinical-
Trials.gov identifier NCT00970801) was conducted to evaluate
drug interactions between AZM and RIF and the association be-
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tween AZM Cmax and treatment outcomes in patients with
MAC-LD who received daily or intermittent AZM-based antibi-
otic treatment regimens.
MATERIALS AND METHODS
Study populations. This is a retrospective study investigating NTM lung
disease, with some data prospectively collected for research purposes from
an ongoing, institutional review board-approved, prospective, and obser-
vational cohort study that took place at Samsung Medical Center (a 1,961-
bed university-affiliated tertiary referral hospital in Seoul, South Korea)
between December 2012 and November 2013. Patients were identified
using the NTM registry database of the Samsung Medical Center (10, 12,
16). The institutional review board (IRB) of the Samsung Medical Center
approved this study and waived the requirement for additional informed
consent (IRB no. 2015-05-111), as we used only deidentified data pro-
spectively collected for research purposes.
Between December 2012 and November 2013, 176 patients were
treated for MAC-LD with AZM-based antibiotic regimens and underwent
TDM (Fig. 1). Of these patients, 10 patients who received antibiotic treat-
ment for12 months (n 8) or who had MAC isolates that were resistant
to CLR (n 2) were excluded. As a control group in this study, 55 patients
with LD due to Mycobacterium abscessus complex (MABC-LD) who un-
derwent TDM for their plasma AZM levels during the same period were
included, and their plasma AZM levels were compared with those of pa-
tients with MAC-LD. Because patients with MABC-LD received oral
AZM without RIF during the entire treatment period (17–19), RIF-asso-
ciated drug interactions could not influence their plasma AZM levels. A
total of 166 patients with MAC-LD, including 77 patients who received
daily antibiotic therapy and 89 patients who received intermittent antibi-
otic therapy, were used to evaluate the relationship between plasma AZM
levels and microbiological treatment responses. All patients met the diag-
nostic criteria for NTM lung disease, according to the guidelines of the
ATS and IDSA (3).
Antibiotic treatment. All patients with MAC-LD who began antibi-
otic therapy received the standardized combination of antibiotic therapy
consisting of oral AZM, RIF, and EMB (3). For patients with cavitary
MAC-LD, including the fibrocavitary and cavitary nodular bronchiectatic
forms, and patients with previously treated MAC-LD, the following daily
regimen was administered: (i) 250 mg/day AZM, (ii) 15 mg/kg of body
weight/day EMB, and (iii) 450 mg/day (body weight, 50 kg) or 600
mg/day (body weight, 50 kg) RIF. Streptomycin was administered in-
tramuscularly in some patients with severe fibrocavitary disease. For pa-
tients with noncavitary nodular bronchiectatic disease, the following in-
termittent regimen was administered: (i) 500 mg AZM, (ii) 25 mg/kg
EMB, and (iii) 600 mg RIF three times weekly.
Drug susceptibility tests were performed at the Korean Institute of
Tuberculosis (Cheongju, South Korea). The MICs of CLR were deter-
mined by the broth microdilution method. MAC isolates with MICs of 32
mg/ml or greater were considered to be resistant to CLR (20). Drug sus-
ceptibility tests for AZM were not performed during the study period.
Sputum examinations for acid-fast bacilli (AFB) were performed 1, 3,
and 6 months after the initiation of antibiotic treatment and then at 2- to
3-month intervals until the end of treatment during the study period (12).
Sputum conversion was defined as three consecutive negative cultures,
and a favorable treatment outcome was defined as sputum culture con-
version and maintenance of negative sputum cultures for more than 12
months (12).
Therapeutic drug monitoring. TDM for AZM was available and has
been included in the research protocol at our institution since December
2012. Peripheral venous blood sampling was performed after 2 weeks of
AZM treatment in the majority of patients (163/166 [98%]) with
MAC-LD and 44/55 (80%) patients with MABC-LD. Samples were taken
2 h after drug intake to estimate the Cmax (21).
Plasma concentrations of AZM, RIF, and EMB were determined with
a Waters 2795 Alliance high-performance liquid chromatographic system
and a Quattro Micro API tandem mass spectrometer (Waters, Man-
chester, United Kingdom). The linear ranges of the assay were 0.25 to 2.5
g/ml for AZM, 0.5 to 50g/ml for RIF, and 0.5 to 10g/ml for EMB. The
intra- and interday precisions, expressed as coefficient variations, were
less than 10%. In accordance with previously published reference ranges,
Cmax values were dichotomized as either normal or low, with low concen-
trations defined as 0.2 g/ml for AZM, 8 g/ml for RIF, and 2
g/ml for EMB (13).
Statistical analyses. All data are presented as medians and interquar-
tile ranges (IQR) for the continuous variables and as numbers (percent-
ages) for the categorical variables. The data were compared using the
Mann-WhitneyU test or Kruskal-Wallis test with post hoc paired compar-
isons using the Bonferroni method for continuous variables and Pearson
2 test or Fisher’s exact test for categorical variables.
To assess whether the Cmax values of AZM, RIF, and EMB were asso-
FIG 1 Treatment regimens and responses of study population. Flow chart shows the treatment regimens and microbiologic responses for the MAC-LD patients
and MABC-LD control group. AZM, azithromycin; EMB, ethambutol; LD, lung disease; MABC, M. abscessus complex; MAC, M. avium complex; RIF, rifampin;
TDM, therapeutic drug monitoring.
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ciated with favorable microbiologic responses in patients with MAC-LD,
we first log-transformed the Cmax of AZM, RIF, and EMB to achieve a
normal distribution and to mitigate the effects of outliers. Then, we per-
formed multivariable logistic regressions in each daily and intermittent
therapy group while adjusting for the variables with a P value of0.25 in
the univariable analysis. In addition, multivariable logistic regressions
were performed with binomial data with referenced cut points (Cmax of
AZM,0.2g/ml; Cmax of RIF,8g/ml; and Cmax of EMB,2g/ml)
instead of continuous variables as AZM, RIF, and EMB Cmax.
If correlations were shown between the Cmax of each drug and favor-
able outcomes, we calculated the Youden index at each cut point to deter-
mine the best cut point of the Cmax of each drug associated with favorable
outcomes (22). Finally, to confirm associations between a new cut point
and a favorable outcome, multivariable logistic regressions were per-
formed with a new cut point. All statistical analyses were performed with
PASW 18.0 (SPSS Inc., Chicago, IL), and a two-sidedP value of0.05 was
considered significant.
RESULTS
Baseline characteristics. The baseline characteristics of patients
with MAC-LD and MABC-LD are presented in Table 1. Of the 166
patients with MAC-LD, 68 (41.0%) were male. The median age
was 61 years (IQR, 52 to 69 years), and the median body mass
index was 20.1 kg/m2 (IQR, 18.5 to 21.8 kg/m2). None of the
patients were positive for human immunodeficiency virus infec-
tion.
Seventy-seven patients (46.4%) received daily therapy, and
89 patients (53.6%) with the noncavitary nodular bronchiec-
tatic form of MAC-LD received intermittent therapy. Of the 77
patients receiving daily therapy, 66 (85.7%) had cavitary MAC-
LD, including either fibrocavitary disease (n  26) or cavitary
nodular bronchiectatic disease (n  40), seven (9.1%) had a
history of previous treatment for NTM lung disease with mac-
rolide-based antibiotic regimens, and four (5.2%) had a non-
classifiable form of the disease, such as noncavitary consolidation
on chest computed tomography (Table 1). Patients receiving
daily therapy had lower body mass indexes, a more frequent
history of previous tuberculosis, more frequent fibrocavitary
disease, and sputum smears that were more frequently positive
for acid-fast bacilli than did patients receiving intermittent




(n 55)Total (n 166) Daily therapy (n 77)
Intermittent therapy
(n 89) P value
Sex, male 68 (41.0) 33 (42.9) 35 (39.3) 0.645 16 (29.1)
Age (yr) 61 (52–69) 59 (51–70.5) 61 (52.5–68.5) 0.707 56 (50–64)
Body mass index (kg/m2) 20.1 (18.5–21.8) 19.8 (17.5–21.2) 20.7 (19.0–22.2) 0.003 20.5 (19.1–22.3)
Nonsmoker 163 (98.2) 75 (97.4) 88 (98.9) 0.597 53 (96.4)
Comorbid disease
Bronchiectasis 137 (82.5) 52 (67.5) 85 (95.5) 0.001 45 (81.8)
Previous tuberculosis 80 (48.2) 49 (63.6) 31 (34.8) 0.001 37 (67.3)
Previous NTM lung
disease
25 (15.1) 13 (16.9) 12 (13.5) 0.541 6 (10.9)
Cancer 33 (19.9) 16 (20.8) 17 (19.1) 0.787 4 (7.3)
Chronic lung diseasec 11 (6.6) 9 (11.7) 2 (2.2) 0.015 3 (5.5)
Diabetes mellitus 10 (6.0) 4 (5.2) 6 (6.7) 0.753 0
Chronic liver disease 8 (4.8) 5 (6.5) 3 (3.4) 0.474 3 (5.5)
Chronic heart disease 5 (3.0) 2 (2.6) 3 (3.4) 1.000 4 (7.3)
Chronic kidney disease 2 (1.2) 1 (1.3) 1 (1.1) 1.000 0
Etiology
Mycobacterium avium 87 (52.4) 36 (46.8) 51 (57.3) 0.175
Mycobacterium
intracellulare
79 (47.6) 41 (53.2) 38 (42.7)





Fibrocavitary form 26 (15.7) 26 (33.8) 0 0.001 12 (21.8)
Nodular bronchiectatic
form
132 (79.5) 47 (61.0) 85 (95.5) 42 (76.4)
Unclassifiable form 8 (4.8) 4 (5.2) 4 (4.5) 1 (1.8)
Cavity on chest HRCTd 66 (39.8) 66 (85.7) 0 0.001 29 (52.7)
Positive sputum smeard 76 (45.8) 53 (68.8) 23 (25.8) 0.001 39 (70.9)
a Data are presented as median (interquartile range) or as number (%).
b NTM, nontuberculous mycobacteria; HRCT, high-resolution computed tomography.
c Chronic lung disease included chronic obstructive pulmonary disease (n 5), interstitial lung disease (n 2), and chronic pulmonary aspergillosis (n 9). Some patients had
more than one chronic lung disease.
d At the initiation of antibiotic treatment.
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therapy. All patients had CLR-susceptible MAC isolates at
treatment initiation.
Cmax of AZM according to treatment regimen. As shown in
Fig. 2, the Cmax values of AZM were significantly lower in patients
with MAC-LD receiving daily therapy that included both AZM
and RIF (median Cmax, 0.22g/ml; IQR, 0.13 to 0.47g/ml) than
in patients with MABC-LD receiving AZM without RIF (median
Cmax, 0.53g/ml; IQR, 0.29 to 0.77g/ml; P 0.001). In patients
with MAC-LD who received intermittent therapy, which included
both AZM and RIF, the AZM Cmax (median, 0.66 g/ml; IQR,
0.18 to 1.32g/ml) was higher than that in patients with MAC-LD
receiving daily therapy (P 0.001). In addition, 46.8% (36/77) of
MAC-LD patients receiving daily therapy had an AZMCmax below
the target of 0.2 g/ml, which was a higher proportion than that
found with patients receiving intermittent therapy for MAC-LD
(25.8% [23/89], P  0.005) or daily therapy without RIF for
MABC-LD (16.4% [9/55], P  0.001). The Cmax of RIF did not
differ between patients receiving daily therapy (median, 12.5 g/
ml; IQR, 7.6 to 17.6g/ml) or intermittent therapy (median, 11.3
g/ml; IQR, 4.5 to 21.2 g/ml; P 0.788). However, the Cmax of
EMB was lower in patients receiving daily therapy (median, 2.8
g/ml; IQR, 1.8 to 4.2g/ml) than in those receiving intermittent
therapy (median, 3.8 g/ml; IQR, 2.2 to 5.8 g/ml; P  0.009).
The median AZM Cmax values and the proportion of patients
whose AZM Cmax was below the target of 0.2 g/ml did not differ
significantly between patients with MAC-LD receiving intermit-
tent therapy and patients with MABC-LD.
Cmax of AZM andmicrobiological responses. Patients receiv-
ing the intermittent therapy for noncavitary treatment-naive
MAC-LD had a higher favorable microbiological response (73/89
[82.0%]) than those receiving the daily therapy for cavitary or
previously treated MAC-LD (52/77 [67.5%],P 0.031), but given
that cavitary disease is a more severe form of MAC-LD, it is un-
clear from these findings how the therapy regimen, versus disease
status, factored into the differing microbiological responses
between the two groups. Within each group, however, there were
no significant differences in the demographic data, disease status,
and treatment details between patients with favorable and unfa-
vorable microbiological responses, except for a higher AFB-posi-
tive smear rate in patients with unfavorable microbiological re-
sponses than in those with favorable microbiological response
(50.0% versus 20.5%, P  0.025) in the intermittent therapy
group (Table 2).
Table 3 shows the associations between the Cmax of AZM, RIF,
and EMB and microbiological response according to treatment
regimen. In the daily therapy group, a higher Cmax of AZM was
associated with a favorable microbiological response (adjusted
odds ratio [OR], 1.58; 95% confidence interval [CI], 1.01 to 2.48;
P  0.044). Although the association between microbiological
response and a cutoff value of 0.2 g/ml was not statistically sig-
nificant, a Cmax for AZM of 0.4 g/ml, which was the best cut
point with the highest Youden index, was significantly associated
with favorable outcomes (adjusted OR, 3.98; 95% CI, 1.06 to
14.85; P 0.040) (see Table S1 in the supplemental material). In
the intermittent therapy group, the higher Cmax of AZM was not
associated with favorable microbiological response (adjusted OR,
0.85; 95% CI, 0.58 to 1.23; P  0.379). In addition, a referenced
cut point of 0.2 g/ml was not associated with microbiological
response (adjusted OR, 1.01; 95% CI, 0.27 to 3.72; P 0.991) in
the intermittent therapy group. The Cmax levels of RIF and EMB
were not associated with the microbiologic response in either the
daily or intermittent therapy group (Table 3).
DISCUSSION
This study evaluated the associations between the Cmax of AZM
and the microbiologic response in patients with MAC-LD, as well
as the effects of RIF on the Cmax of AZM. A high Cmax of AZM was
associated with a favorable microbiological response in patients
with MAC-LD treated with a daily AZM-based regimen, although
this association was not found in patients treated with an inter-
mittent regimen. In addition, we found that RIF significantly re-
duced the Cmax of AZM when used in a daily regimen.
Although the use of TDM in the treatment of patients with
tuberculosis has become more widely accepted (23–26), there are
few reports of the clinical usefulness of TDM in patients with
NTM lung disease (13–15). We previously reported that low
plasma CLR concentrations were common in patients treated for
MAC-LD, although we found no association between low plasma
CLR concentrations and treatment outcomes (14). However,
there have been no reports on the associations between theCmax of
AZM and treatment outcomes in patients with MAC-LD.
Several reports have been published on the pharmacokinetics
and pharmacodynamics of AZM in patients with MAC-LD (13,
15, 27). To the best of our knowledge, however, there has only
been one report on the interaction between Cmax of AZM and the
use of RIF in patients with MAC-LD (13). That study demon-
strated that the Cmax of AZM decreased by 23% from 0.35 g/ml
to 0.27g/ml in conjunction with the administration of RIF (13).
Our study showed that theCmax of AZM was 58% lower in patients
with MAC-LD who received daily AZM with rifampin (median,
0.22 g/ml) than that in patients with MABC-LD who received
daily AZM without RIF (median, 0.53 g/ml). Although a signif-
FIG 2 A box-and-whisker plot of peak plasma azithromycin concentrations.
The bottom and top of each box indicate the 25th and 75th percentiles, respec-
tively, and the line within each box indicates the median. The whiskers indicate
the 10th and 90th percentiles. AZM Cmax, peak plasma azithromycin concen-
trations; MABC, M. abscessus complex; MAC, M. avium complex.
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icant lowering of the AZM Cmax in conjunction with RIF was
found in the present study, AZM seems to be less influenced by
RIF than does CLR, as demonstrated by our previous study in
which we observed a 92% reduction from a medianCmax of CLR of
3.8 g/ml in patients with MABC-LD to a median Cmax of 0.3
g/ml in patients with MAC-LD who received both CLR (1,000
mg/day) and RIF (14).
In addition, no reports on the interaction between AZM and
RIF in an intermittent regimen for the treatment of noncavitary
nodular bronchiectatic MAC-LD have been published. In our pre-
vious study, the Cmax levels of CLR (median, 0.2 g/ml) in
MAC-LD patients, with an intermittent CLR-based multidrug
regimen that included RIF, were significantly lower (95%) than
those (median, 3.8 g/ml) in MABC-LD patients (14). In the
present study, the Cmax of AZM (median, 0.66 g/ml) in the in-
termittent AZM-based multidrug regimen in MAC-LD patients
was not lower than that in patients with MABC-LD (median, 0.53
g/ml). This might be due to the use of a higher dosage of AZM in
the intermittent regimen (500 mg) than in the daily regimen (250
mg) and also due to less interaction between AZM and RIF than
between CLR and RIF.
Pharmacokinetic studies on AZM, like other macrolide antibi-
otics, have shown low plasma levels and high tissue concentrations
(28, 29). Although the Cmax of AZM after a single 500-mg oral
dose is 5-fold lower than the Cmax of CLR using the same dose
(30), the ratio of tissue concentrations to plasma levels for AZM
(10- to 100-fold) is higher than that for CLR (2- to 20-fold) (31–
33). In combination with RIF, the induction of cytochrome P450
enzymes metabolizes CLR to its main metabolite, the 14-hydroxy
form, which is 10 to 30 times less active against MAC in vitro (34,
35). However, AZM has no active metabolites, does not interact
with cytochrome P450, and is eliminated in the feces as an un-
changed drug (29, 36, 37). Therefore, AZM may be more advan-
tageous than CLR in macrolide-based multidrug regimens with
RIF (13).
This study is the first to document the relationship between the
Cmax of AZM and treatment responses in patients with MAC-LD
under different treatment regimens. Our patients with MAC-LD
were treated in accordance with the current guidelines (3), which
recommend intermittent therapy for patients with treatment-
naive noncavitary nodular bronchiectatic disease and daily ther-
apy for patients with cavitary disease or previously treated disease.
In patients who received an intermittent regimen that included
500 mg of AZM three times weekly, favorable microbiological
responses and an AZM Cmax of 0.2 g/ml were achieved in
82.0% (73/89) and 74.2% (66/89) of patients, respectively. There
was no association between the AZM Cmax and microbiological
response in patients who received intermittent therapy, and the
basis for this is unclear. However, it is possible that given the high
Cmax achieved in this study group and the milder disease, the
threshold level of AZM needed for effectiveness was present in the
majority of patients, and that other factors were greater determi-
TABLE 2 Characteristics, treatment regimens, and microbiologic responses of 166 patients with M. avium complex lung diseasea
Characteristic












responses (n 16) P value
Sex, male 21 (40.4) 12 (48.0) 0.527 27 (37.0) 8 (50.0) 0.334
Age (yr) 60 (51–69.5) 59 (52–71) 0.853 61 (53.5–69) 59.5 (50–67.5) 0.567
Body mass index (kg/m2) 19.8 (17.5–20.7) 20.2 (16.9–22.0) 0.355 20.9 (19.1–22.3) 19.6 (17.9–22.0) 0.283
Nonsmoker 76 (98.1) 24 (96.0) 0.547 72 (98.6) 16 (100) 1.000
Comorbid disease
Bronchiectasis 37 (71.2) 15 (60.0) 0.328 70 (95.9) 15 (93.8) 0.554
Previous tuberculosis 33 (63.5) 16 (64.0) 0.963 24 (32.9) 7 (43.8) 0.408
Previous NTM lung disease 10 (19.2) 3 (12.0) 0.529 10 (13.7) 2 (12.5) 1.000
Cancer 12 (23.1) 4 (16.0) 0.474 13 (17.8) 4 (25.0) 0.497
Chronic lung disease 5 (9.6) 4 (16.0) 0.461 2 (2.7) 0 1.000
Diabetes mellitus 3 (5.8) 1 (4.0) 1.000 6 (8.2) 0 0.586
Chronic liver disease 2 (3.8) 3 (12.0) 0.322 3 (4.1) 0 1.000
Chronic heart disease 1 (1.9) 1 (4.0) 0.547 2 (2.7) 1 (6.3) 0.452
Chronic kidney disease 1 (1.9) 0 1.000 1 (1.4) 0 1.000
Etiology 0.190 0.226
M. avium 27 (51.9) 9 (36.0) 44 (60.3) 7 (43.8)
M. intracellulare 25 (48.1) 16 (64.0) 29 (39.7) 9 (56.3)
Fibrocavitary form 15 (28.8) 11 (44.0) 0.188 0 0
Positive sputum smearb 34 (65.4) 21 (84.0) 0.065 15 (20.5) 8 (50.0) 0.025
Additional treatmentc
Injectable drugs 11 (21.2) 10 (40.0) 0.082 0 0
Surgical resection 3 (5.8) 3 (12.0) 0.383 0 0
a Data are presented as median (interquartile range) or number (%).
b At the initiation of antibiotic treatment.
c Within 12 months of the start of antibiotic treatment.
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nants of outcome. In patients who received a daily regimen that
included 250 mg of daily AZM, favorable microbiological re-
sponses and an AZM Cmax of 0.2 g/ml were achieved in only
67.5% (52/77) and 53.2% (41/77) of patients, respectively. In con-
trast to the intermittent-therapy group, a higher Cmax of AZM was
associated with a favorable microbiological response in patients
receiving daily therapy. However, the overall poorer responses of
patients on daily therapy may be largely due to the greater severity
of cavitary disease than noncavitary disease.
The currently recommended treatment regimens for MAC-LD
resulted in significant drug interactions and low Cmax levels of
AZM, which is the most important drug within the regimen,
especially in patients who receive daily therapy. Several modifica-
tions, such as increased AZM doses or replacement of RIF with
another drug, may increase the Cmax of AZM and improve treat-
ment outcomes in severe MAC-LD. A daily AZM-based regimen
with a higher dose of AZM has not been fully evaluated for its
efficacy and safety in the treatment of MAC-LD. A previous study
reported that a daily 600-mg AZM-based regimen resulted in
higher AZM Cmax than did a daily 300-mg AZM-based regimen
(27). However, a higher dose of AZM was associated with more
frequent complications, such as gastrointestinal symptoms and
hearing impairment (27). Interestingly, a recent study using the
hollow-fiber system model of MAC suggested that 500 mg of AZM
might be also suboptimal and that higher doses of AZM may be
necessary to treat MAC-LD (38). Another possible means to in-
crease the AZM Cmax is to use a two-drug regimen (AZM and
EMB) without RIF or with the substitution of other drugs, such as
clofazimine, for RIF. A preliminary randomized study showed
that the clinical efficacy of a daily two-drug regimen (CLR and
EMB) was similar to that of a daily three-drug regimen (CLR,
EMB, and RIF) for MAC-LD (39). In addition, the replacement of
RIF with clofazimine and daily treatment with CLR or AZM,
EMB, and clofazimine achieved similar treatment outcomes in
patients with MAC-LD in two retrospective studies (40, 41). Fur-
ther clinical studies are warranted to evaluate these treatment op-
tions for MAC-LD.
This study has several limitations. First, this retrospective study
was performed at a single referral center. Second, only one sample
was collected after 2 h of drug administration in the outpatient
clinical setting. Third, drug susceptibility tests for AZM were not
performed during the study period. Therefore, we could not eval-
uate the associations between Cmax and MIC (Cmax/MIC) or the
area under the curve (AUC)/MIC of AZM. Fourth, we did not
measure AZM concentrations in the epithelial lining fluid or in
alveolar macrophages at the site of MAC infection. Finally, there
was no validation group for confirming the associations between
the new cut point of Cmax AZM (0.4g/ml) and favorable treat-
ment responses in patients with MAC-LD who received daily ther-
apy. Therefore, the generalizability of our findings may be limited,
and further large-scale studies are needed to evaluate the associa-
tions between the pharmacokinetics and pharmacodynamics of
the investigated drugs and microbiological response.
In summary, a low AZM Cmax was common in patients receiv-
ing a daily AZM-based multidrug regimen for MAC-LD, and a
higher AZM Cmax was associated with favorable microbiologic
outcomes. When a daily AZM-based multidrug regimen is used
for treating severe MAC-LD, such as cavitary disease, the currently
recommended AZM dose may be suboptimal. Further analyses,
including investigating the effects of increased AZM doses or sub-
stituting RIF with another drug, are needed to confirm the asso-
ciations between AZM Cmax and microbiologic outcomes.
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TABLE 3 Associations between estimated Cmax of the antibiotics and microbiological response according to treatment regimen
a
Therapy type Cmax (g/ml) by drug
b Favorable responses Unfavorable responses
Univariate analysis Multiple logistic regressionc
OR (95% CI) P aOR (95% CI) P
Daily AZM 0.24 (0.14–0.51) 0.18 (0.08–0.35) 1.53 (1.01–2.31) 0.045 1.58 (1.01–2.48) 0.044
AZM0.2 29/52 (55.8) 12/25 (48.0) 1.37 (0.53–3.56) 0.523 1.45 (0.52–4.04) 0.476
AZM0.4 21/52 (40.4) 4/25 (16.0) 3.56 (1.07–11.86) 0.039 3.98 (1.06–14.85) 0.040
RIFd 11.2 (7.4–15.1) 13.7 (8.3–20.4) 0.92 (0.64–1.34) 0.678 1.00 (0.66–1.52) 0.989
RIF8.0 36/52 (69.2) 20/25 (80.0) 0.56 (0.18–1.76) 0.324 0.68 (0.19–2.38) 0.545
EMBd 3.4 (1.8–4.6) 2.4 (1.7–3.5) 1.34 (0.79–2.25) 0.279 1.30 (0.73–2.31) 0.367
EMB2.0 37/52 (71.2) 17/25 (68.0) 1.16 (0.41–3.26) 0.777 1.14 (0.38–3.46) 0.810
Intermittent AZMd 0.65 (0.18–1.31) 1.00 (0.18–1.44) 0.84 (0.59–1.19) 0.322 0.85 (0.58–1.23) 0.379
AZM0.2 54/73 (74.0) 12/16 (75.0) 0.95 (0.27–3.30) 0.932 1.01 (0.27–3.72) 0.991
RIFd 11.2 (3.0–21.6) 12.0 (6.5–19.5) 0.87 (0.64–1.18) 0.382 0.93 (0.67–1.27) 0.636
RIF8.0 47/73 (64.4) 11/16 (68.8) 0.82 (0.26–2.62) 0.740 1.12 (0.33–3.84) 0.861
EMBd,e 3.5 (2.0–5.6) 4.8 (3.0–6.6) 0.65 (0.35–1.21) 0.177 0.63 (0.33–1.23) 0.176
EMB2.0 55/72 (76.4) 14/16 (87.5) 0.46 (0.10–2.24) 0.338 0.41 (0.08–2.13) 0.291
a Data are presented as median (interquartile range) or number/total number (%). CI, confidence interval; OR and aOR, odds ratio and adjusted odds ratio, respectively.
b AZM, azithromycin; Cmax, peak plasma concentration; EMB, ethambutol; RIF, rifampin.
c In univariate and multiple logistic regression analyses, the Cmax of each drug was analyzed after log2 transformation.
d Adjusted for etiologic pathogen, fibrocavitary disease, positive sputum smear, and use of injectable drugs in patients with daily therapy and adjusted for etiologic pathogen and
positive sputum smear in patients with intermittent therapy.
e One patient with favorable response had a missing Cmax value for EMB.
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